Last reviewed · How we verify
NCT04202835
ATG Plus PTCy vs ATG for CGVHD Prophylaxis
Active, enrolled
Phase 2
Last updated 11 May 2025
What this trial tests
Phase 2 trial testing Cyclophosphamide in Acute Leukemia in 80 participants. Participants enrolled and being followed up; not accepting new ones.
Timeline
14 October 2020
Primary endpoint
18 May 2024
18 May 2024
7 February 2026
Quick facts
| Lead sponsor | McMaster University |
|---|---|
| Phase | Phase 2 |
| Status | Active, enrolled |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 80 |
| Start date | 14 October 2020 |
| Primary completion | 18 May 2024 |
| Estimated completion | 7 February 2026 |
| Sites | 9 locations across Canada, Australia |
Drugs / interventions tested
- Cyclophosphamide (cyclophosphamide) — full drug profile →
- Anti-Thymocyte globulin (rabbit) — full drug profile →
Conditions studied
- Acute Leukemia — all drugs for Acute Leukemia →
- Myelodysplasia — all drugs for Myelodysplasia →
- Chronic Graft-versus-host-disease — all drugs for Chronic Graft-versus-host-disease →
Sponsor
McMaster University
Who can join
Adults 16 to 70, any sex, with Acute Leukemia or Myelodysplasia. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Randomized Pilot Trial to test the feasibility of comparing anti-thymocyte globulin plus post transplant cyclophosphamide with anti-thymocyte globulin alone to prevent chronic graft versus host disease.
Publications & conference data
4 peer-reviewed publications reference this trial (live from Europe PMC):
-
Post-transplantation Cyclophosphamide: From HLA-Haploidentical to Matched-Related and Matched-Unrelated Donor Blood and Marrow Transplantation.
Williams L, Cirrone F, Cole K, Abdul-Hay M, et al · · 2020 · cited 32× · PMID 32373119 · DOI 10.3389/fimmu.2020.00636 -
Immunopathogenic mechanisms and modulatory approaches to graft-versus-host disease prevention in acute myeloid leukaemia.
Pang Y, Holtzman NG. · · 2023 · cited 3× · PMID 37353287 · DOI 10.1016/j.beha.2023.101475 -
Novel approaches to acute graft-versus-host disease prevention.
Watkins B, Qayed M. · · 2023 · cited 2× · PMID 38066861 · DOI 10.1182/hematology.2023000426 -
The Development of New Agents for Post-Hematopoietic Stem Cell Transplantation Non-Infectious Complications in Children.
Ilan U, Brivio E, Algeri M, Balduzzi A, et al · · 2023 · cited 2× · PMID 36983151 · DOI 10.3390/jcm12062149
Verify or expand the search:
- PubMed search for NCT04202835
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Cyclophosphamide
Trials testing the same drug.
- NCT07137481 — Phase II Study of CD5 CAR Engineered IL15-transduced Cord Blood-derived NK Cells in Conjunction With Lymphodepleting Che · Phase 2 · not yet recruiting
- NCT07509008 — Phase 1/2 Window Of Opportunity Study Of TROP2 CAR/IL-15 TGFBR2 KO NK Cells Delivered Intraperitoneally For The Manageme · Phase 1, PHASE2 · not yet recruiting
- NCT07444632 — Phase1 Basket Trial Of CAR.70-Engineered IL15-Transduced With TGFBR2 Knock Out Cord Blood-Derived NK Cells For Relapsed/ · Phase 1 · not yet recruiting
- NCT07444710 — Testing the Addition of an Anti-Cancer Drug, Glofitamab, to the Usual Chemotherapy Treatment (Alternating R-CHOP/R-DHAP) · Phase 1 · not yet recruiting
- NCT07437963 — Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatmen · Phase 1, PHASE2 · not yet recruiting
Other recruiting trials for Acute Leukemia
Currently open trials in the same condition.
- NCT07270770 — BY002 IIT Study in R/R Acute Leukemia · Phase 1 · recruiting
- NCT07356154 — A Study of Revumenib and Mezigdomide in People With Leukemia · Phase 1, PHASE2 · recruiting
- NCT07362095 — Luspatercept for the Treatment of Anemia Following Allogeneic Hematopoietic Stem Cell Transplantation(Allo-HSCT) · Phase 1, PHASE2 · recruiting
- NCT07101497 — Phase 2 Trial of BN104 as Post-HSCT Maintenance in Acute Leukemia · Phase 2 · recruiting
- NCT06984536 — Reduced ATG Plus Mini PTCy for GVHD Prophylaxis in Haplo-SCT · Phase 2 · recruiting
Other McMaster University trials
Trials by the same sponsor.
- NCT06231069 — Mixed Exercise Training and Novel Multi-Nutrient Supplementation in Young Adults · NA · withdrawn
- NCT07213492 — Multimodal Intervention to Support Hospital-to-Community Transition in Bipolar Disorder · NA · recruiting
- NCT07486505 — Mindfulness in Fracture Recovery and Reduction of Opioid Reliance: Evaluating the Feasibility of Implementing a Brief, M · NA · not yet recruiting
- NCT07408128 — Partner4Exercise Randomized Controlled Trial · Phase 2, PHASE3 · not yet recruiting
- NCT07459777 — Early arthroscoPic Stabilization veRsus rehabilitatiOn of the Shoulder in Adolescents With a trauMatic First-time Anteri · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
Data sources for this page
- Trial protocol + status: ClinicalTrials.gov NCT04202835 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by McMaster University
- Last refreshed: 11 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04202835.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing